Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Monte Rosa Therapeutics, Inc.
13G
GLUE · 61225M102
|
5.4% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 5.4% | ||||
| Ryan Wilder | 5.4% | ||||
|
Myriad Genetics Inc
13G
MYGN · 62855J104
|
6.1% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 6.1% | ||||
| Ryan Wilder | 6.1% | ||||
|
Solid Biosciences Inc.
13G/A
Amendment 2
SLDB · 83422E204
|
4.8% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 4.8% | ||||
| Ryan Wilder | 4.8% | ||||
|
Immunocore Holdings plc
13G/A
Amendment 1
IMCR · 45258D105
|
3.5% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 3.5% | ||||
| Ryan Wilder | 3.5% | ||||
|
Nurix Therapeutics, Inc.
13G/A
Amendment 1
NRIX · 67080M103
|
7.8% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 7.8% | ||||
| Ryan Wilder | 7.8% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 2
ANRO · 02157Q109
|
2.2% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 2.2% | ||||
| Ryan Wilder | 2.2% | ||||
|
iBio, Inc.
13G/A
Amendment 1
IBIO · 451033708
|
7.9% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 7.9% | ||||
| Ryan Wilder | 7.9% | ||||
|
Passage BIO, Inc.
13G/A
Amendment 1
PASG · 702712209
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Vestal Point Capital, LP | 0% | ||||
| Ryan Wilder | 0% | ||||
|
Taysha Gene Therapies, Inc.
13G/A
Amendment 1
TSHA · 877619106
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 6.3% | ||||
| Ryan Wilder | 6.3% | ||||
|
Bicara Therapeutics Inc.
13G/A
Amendment 3
BCAX · 055477103
|
8.3% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 8.3% | ||||
| Ryan Wilder | 8.3% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 1
ELVN · 29337E102
|
5.4% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 5.4% | ||||
| Ryan Wilder | 5.4% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 1
ANRO · 02157Q109
|
6.5% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 6.5% | ||||
| Ryan Wilder | 6.5% | ||||
|
Immatics N.V.
13G/A
Amendment 1
IMTX · N44445109
|
4.6% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 4.6% | ||||
| Ryan Wilder | 4.6% | ||||
|
Arcellx, Inc.
13G/A
Amendment 1
ACLX · 03940C100
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 0% | ||||
| Ryan Wilder | 0% | ||||
|
Day One Biopharmaceuticals, Inc.
13G/A
Amendment 1
DAWN · 23954D109
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 0% | ||||
| Ryan Wilder | 0% | ||||
|
Bright Minds Biosciences Inc.
13G
DRUG · 10919W405
|
5.0% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 5.0% | ||||
| Ryan Wilder | 5.0% | ||||
|
Nurix Therapeutics, Inc.
13G
NRIX · 67080M103
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 6.3% | ||||
| Ryan Wilder | 6.3% | ||||
|
Aprea Therapeutics, Inc.
13G
APRE · 03836J201
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 9.9% | ||||
| Ryan Wilder | 9.9% | ||||
|
Immunocore Holdings plc
13G
IMCR · 45258D105
|
5.5% |
5/15/2026
Event 3/31/2026
|
|||
| Vestal Point Capital, LP | 5.5% | ||||
| Ryan Wilder | 5.5% | ||||
|
Bicara Therapeutics Inc.
13G/A
Amendment 2
BCAX · 055477103
|
6.5% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 6.5% | ||||
| Ryan Wilder | 6.5% | ||||
|
Astria Therapeutics, Inc.
13G/A
Amendment 2
ATXS · 04635X102
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 0% | ||||
| Ryan Wilder | 0% | ||||
|
Black Diamond Therapeutics, Inc.
13G/A
Amendment 1
BDTX · 09203E105
|
1.5% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 1.5% | ||||
| Ryan Wilder | 1.5% | ||||
|
Applied Therapeutics, Inc.
13G/A
Amendment 1
APLT · 03828A101
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 0% | ||||
| Ryan Wilder | 0% | ||||
|
Solid Biosciences Inc.
13G
SLDB · 83422E204
|
7.5% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 7.5% | ||||
| Ryan Wilder | 7.5% | ||||
|
Taysha Gene Therapies, Inc.
13G
TSHA · 877619106
|
5.0% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 5.0% | ||||
| Ryan Wilder | 5.0% | ||||
|
Enliven Therapeutics, Inc.
13G
ELVN · 29337E102
|
6.5% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 6.5% | ||||
| Ryan Wilder | 6.5% | ||||
|
Day One Biopharmaceuticals, Inc.
13G
DAWN · 23954D109
|
5.1% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 5.1% | ||||
| Ryan Wilder | 5.1% | ||||
|
Crescent Biopharma, Inc.
13G
CBIO · G2545C104
|
5.4% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 5.4% | ||||
| Ryan Wilder | 5.4% | ||||
|
Arcellx, Inc.
13G
ACLX · 03940C100
|
5.1% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 5.1% | ||||
| Ryan Wilder | 5.1% | ||||
|
Alto Neuroscience, Inc.
13G
ANRO · 02157Q109
|
8.0% |
2/17/2026
Event 12/31/2025
|
|||
| Vestal Point Capital, LP | 8.0% | ||||
| Ryan Wilder | 8.0% | ||||
|
uniQure N.V.
13G/A
Amendment 5
QURE · N90064101
|
0.4% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 0.4% | ||||
| Ryan Wilder | 0.4% | ||||
|
Tenax Therapeutics, Inc.
13G
TENX · 88032L605
|
9.9% |
11/14/2025
Event 9/30/2024
|
|||
| Vestal Point Capital, LP | 9.9% | ||||
| Ryan Wilder | 9.9% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13G/A
Amendment 2
DNTH · 252828108
|
3.0% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 3.0% | ||||
| Ryan Wilder | 3.0% | ||||
|
iBio, Inc.
13G
IBIO · 451033708
|
9.9% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 9.9% | ||||
| Ryan Wilder | 9.9% | ||||
|
Savara Inc
13G/A
Amendment 1
SVRA · 805111101
|
2.3% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 2.3% | ||||
| Ryan Wilder | 2.3% | ||||
|
KalVista Pharmaceuticals, Inc.
13G/A
Amendment 1
KALV · 483497103
|
1.5% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 1.5% | ||||
| Ryan Wilder | 1.5% | ||||
|
Tyra Biosciences, Inc.
13G/A
Amendment 1
TYRA · 90240B106
|
4.5% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 4.5% | ||||
| Ryan Wilder | 4.5% | ||||
|
Astria Therapeutics, Inc.
13G/A
Amendment 1
ATXS · 04635X102
|
8.8% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 8.8% | ||||
| Ryan Wilder | 8.8% | ||||
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 1
LXEO · 52886X107
|
7.5% |
11/14/2025
Event 9/30/2025
|
|||
| Vestal Point Capital, LP | 7.5% | ||||
| Ryan Wilder | 7.5% | ||||
|
uniQure N.V.
13G/A
Amendment 4
QURE · N90064101
|
6.8% |
8/14/2025
Event 6/30/2025
|
|||
| Vestal Point Capital, LP | 6.8% | ||||
| Ryan Wilder | 6.8% | ||||
|
Nyxoah SA
13G/A
Amendment 2
NYXH · B6S7WD106
|
3.7% |
8/14/2025
Event 6/30/2025
|
|||
| Vestal Point Capital, LP | 3.7% | ||||
| Ryan Wilder | 3.7% | ||||
|
Bicara Therapeutics Inc.
13G/A
Amendment 1
BCAX · 055477103
|
9.2% |
8/14/2025
Event 6/30/2025
|
|||
| Vestal Point Capital, LP | 9.2% | ||||
| Ryan Wilder | 9.2% | ||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
6.0% |
8/14/2025
Event 6/30/2025
|
|||
| Vestal Point Capital, LP | 6.0% | ||||
| Ryan Wilder | 6.0% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13G/A
Amendment 1
DNTH · 252828108
|
10.0% |
8/14/2025
Event 6/30/2025
|
|||
| Vestal Point Capital, LP | 10.0% | ||||
| Ryan Wilder | 10.0% | ||||
|
Tyra Biosciences, Inc.
13G
TYRA · 90240B106
|
5.4% |
5/15/2025
Event 3/31/2025
|
|||
| Vestal Point Capital, LP | 5.4% | ||||
| Ryan Wilder | 5.4% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13G
DNTH · 252828108
|
5.3% |
5/15/2025
Event 3/31/2025
|
|||
| Vestal Point Capital, LP | 5.3% | ||||
| Ryan Wilder | 5.3% | ||||
|
Bicara Therapeutics Inc.
13G
BCAX · 055477103
|
5.1% |
5/15/2025
Event 3/31/2025
|
|||
| Vestal Point Capital, LP | 5.1% | ||||
| Ryan Wilder | 5.1% | ||||
|
uniQure N.V.
13G/A
Amendment 3
QURE · N90064101
|
8.9% |
5/15/2025
Event 3/31/2025
|
|||
| Vestal Point Capital, LP | 8.9% | ||||
| Ryan Wilder | 8.9% | ||||
|
Solid Biosciences Inc.
13G/A
Amendment 1
SLDB · 83422E204
|
2.3% |
5/15/2025
Event 3/31/2025
|
|||
| Vestal Point Capital, LP | 2.3% | ||||
| Ryan Wilder | 2.3% | ||||
|
Nyxoah SA
13G/A
Amendment 1
NYXH · B6S7WD106
|
6.2% |
5/15/2025
Event 3/31/2025
|
|||
| Vestal Point Capital, LP | 6.2% | ||||
| Ryan Wilder | 6.2% | ||||
|
Applied Therapeutics, Inc.
13G
APLT · 03828A101
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Vestal Point Capital, LP | 9.9% | ||||
| Ryan Wilder | 9.9% | ||||
|
uniQure N.V.
13G/A
Amendment 2
QURE · N90064101
|
6.2% |
2/14/2025
Event 12/31/2024
|
|||
| Vestal Point Capital, LP | 6.2% | ||||
| Ryan Wilder | 6.2% | ||||
|
Savara Inc
13G
SVRA · 805111101
|
6.3% |
2/14/2025
Event 12/31/2024
|
|||
| Vestal Point Capital, LP | 6.3% | ||||
| Ryan Wilder | 6.3% | ||||
|
Nyxoah SA
13G
NYXH · B6S7WD106
|
7.8% |
2/14/2025
Event 12/31/2024
|
|||
| Vestal Point Capital, LP | 7.8% | ||||
| Ryan Wilder | 7.8% | ||||
|
Immatics N.V.
13G
IMTX · N44445109
|
5.3% |
2/14/2025
Event 12/31/2024
|
|||
| Vestal Point Capital, LP | 5.3% | ||||
| Ryan Wilder | 5.3% | ||||